Peptide Injections at a Longevity Conference: What Actually Went Wrong
After a ProPublica report described attendees hospitalised following peptide injections given at a Las Vegas longevity conference booth, Matt Kaeberlein recorded an emergency episode about what he saw there. His central point: peptides are a huge, varied class of bioactive molecules, not a single safe thing. The episode is a practical lesson in telling solid science from the grey zone and from outright nonsense.
Overview
Matt Kaeberlein had just returned from a three-conference stretch — Dublin, an animal science meeting in Florida, and Radfest in Las Vegas — when a ProPublica article reported that attendees at Radfest had been hospitalised after receiving peptide injections at an exhibitor booth. Two women ended up in critical condition on ventilators with swollen tongues and breathing difficulty; police documents referenced as many as seven hospitalisations.
Kaeberlein describes Radfest as a study in contrasts: the main-stage scientific programme curated by Aubrey de Grey was, in his view, genuinely good, while the exhibitor hall and the on-site 'clinic' ranged from reasonable to pure nonsense. He is careful to separate the people from the practices — most attendees struck him as kind and sincere, but largely unequipped to tell science from science fiction from snake oil. His main scientific correction is that talking about 'peptides' as one thing is like talking about 'drugs' as one thing: they are short chains of amino acids that do wildly different things, and being peptide-shaped says nothing about safety.
He walks through the other therapies on offer — gene therapy, therapeutic plasma exchange, ultrasound bone density, red light, supplements — placing each on a spectrum from well-understood to speculative. He also argues the regulatory story in the article is backwards: peptides have been under-regulated, not over-regulated, which is precisely why nobody can say who benefits and who doesn't. The episode closes with a hotel-room scene involving exosome injections and a practitioner who wanted to 'feel your energy' before dosing.
Key quotes
5Talking about peptides as one thing is kind of like talking about drugs as one thing.
People should not be doing peptide injections in a conference vendor hall.
Talking with a lot of certainty in very general terms is a red flag.
If you're going to be a medical provider giving stuff to people, it is your job to stay up to date.
Please send me as much energy as you want. Just do not stick those syringe needles in me.
Key ideas
9A field where the fringe is creeping onto the main stage
Kaeberlein noticed for the first time at the Dublin conference that less scientific work was being platformed, partly through sponsorship. He sees this apparent legitimisation as one of the field's real risks.
Radfest was two different events at once
The curated main-stage science was strong and unusually diverse. The exhibitor hall and the on-site clinic were a different world, and that is where the injections happened.
Sincere audiences, unequipped filters
He found most attendees kind and genuinely enthusiastic, some with technical backgrounds. What most lacked was any trained way to separate legitimate science from marketing or fantasy.
Freedom over your own body — with guardrails
He supports informed adults choosing their own health path, but draws the line where practices start harming other people. Guardrails are what makes the libertarian position workable.
What the reporting established
Two women were hospitalised in critical condition on ventilators after injections at a booth; police documents referenced as many as seven hospitalisations. Investigators are examining infection, contamination and the medication itself.
'Peptide' describes a shape, not a safety profile
Peptides are short amino acid chains — some bioactive, some not, some naturally occurring, some engineered. They are no safer and no more dangerous as a class than pharmaceutical drugs.
A rough map of the grey zone
Of the clinical and experimental offerings, he ballparks roughly a quarter as rock-solid lifestyle work, half as reasonable-to-be-optimistic, and a quarter as pure nonsense. Plasma exchange and diagnostics sat on the better end.
Compounding is where the real grey area lives
A reputable compounding pharmacy makes drugs to a known standard, but these peptides are not approved products. The risk concentrates in pharmacies that cut corners on active ingredient or contamination.
Weak consequences invite loud claims
When deceptive health claims are met only with a letter telling someone to stop, the incentive to overstate stays intact. Kaeberlein argues this is a structural driver of the noise in the space.
Practical takeaways
6- 1
Treat confident vagueness as a warning sign 37:00
If someone says a compound 'improves mitochondrial function' but cannot explain what that means when asked, they are repeating something rather than knowing it.
- 2
Check the track record before the claim 38:30
A history of regulatory letters, retracted claims or trouble with authorities tells you more about reliability than any brochure will.
- 3
Setting matters as much as substance 31:00
Nobody can meaningfully assess your history in the thirty seconds it takes to draw up a vial in an exhibition hall. A venue without emergency equipment changes the risk profile of anything injected.
- 4
Drop the 'natural means safe' assumption 26:00
Being an amino acid chain says nothing about whether a molecule is safe for you specifically, at that dose, in that context.
- 5
Be selective rather than kitchen-sink with supplements 52:00
Kaeberlein's own bias is toward a short list where deficiency is plausible, on the view that piling compounds onto a complex system is more likely to cause harm than benefit.
- 6
Ask what else is in the vial 54:00
Solvents, preservatives and mixing agents can drive a reaction even when the headline compound does not. The full formulation is part of the question.
Topics & chapters
15Why this became an emergency episode
A ProPublica article lands the morning of recording. Kaeberlein had already planned to share his Radfest reflections.
Three conferences, one worrying trend
Dublin, an animal science meeting, then Radfest. He describes noticing the less scientific side getting prominent stage time.
Radfest: strong main stage, chaotic exhibitor hall
The curated scientific programme impressed him. Off the main stage, the picture was very different.
Who actually attends
Kind, enthusiastic, largely non-scientific audiences — and a movement with an almost devotional feel.
Freedom with guardrails
Where a libertarian view of health holds up, and where it breaks down once other people are being treated.
What happened at the booth
Rumours of eleven, reporting of two critical and up to seven hospitalised. Ventilators, swollen tongues, breathing difficulty.
Peptides are a category, not a drug
Short amino acid chains that do wildly different things — the core misconception the episode is built around.
Is there a longevity peptide?
GLP-1 agonists are the nearest well-characterised example; the class has barely been studied for biological aging.
Why a vendor hall is the wrong setting
No meaningful history-taking, no emergency equipment, no follow-up after the injection.
How to vet a booth or a practitioner
Too-good-to-be-true claims, confident vagueness, 'no side effects', and a sales incentive behind the advice.
Gene therapy, plasma exchange, bone ultrasound, red light
Each therapy placed on the spectrum from well-understood to speculative, with the reasoning behind the placement.
Supplements and the compounding grey area
What 'generally recognised as safe' actually means, and where compounded products genuinely carry risk.
Reading the article line by line
The regulation framing he disputes, the licensing findings, and the claim that a chatbot report cleared the peptides.
Consequences, licences and liability
Weak penalties for deceptive claims, state licensing rules, and the liability exposure for organisers and providers.
The hotel room story
Exosome injections dosed by 'feeling your energy' — the moment that disturbed him most, and what it says about risk tolerance.